Mirati Therapeutics

Mirati Therapeutics, Inc. is an American targeted oncology company that focuses on the development of cancer therapeutics.[1] Bristol Myers Squibb agreed to acquire the company in October 2023.[2]

Mirati Therapeutics, Inc.
TypePublic
IndustryOncology
Founded1995 (1995)
HeadquartersSan Diego, California, U.S.
Key people
David Meek
Number of employees
600 (2022)
Websitemirati.com

History

Mirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.[3] The inhibition to the mutation has shown to shrink the size of its tumors.[4] The company is based in San Diego, California.[5] The company’s name comes from the Italian word for “targeted” (Mirati). Mirati Therapeutics is traded on the NASDAQ[6] under the ticker symbol MRTX.[7] It joined the exchange in 2013.[8]

In October 2023, Bristol Myers Squibb agreed to acquire the company in an all-cash deal worth $4.8 billion, and an additional $1 billion in milestone payment.[2]

Drug candidates

The company’s leading drug candidates are sitravatinib and adagrasib.[5] Mirati also has a preclinical candidate against the G12D mutation.[9]

Management

The company’s CEO and President is David Meek.[10]

References
  1. Flanagan C (25 October 2020). "Hedge Fund Pick Mirati Rallies to Record After Drug Results". BloombergQuint.
  2. Condie, Stuart (8 October 2023). "Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion". The Wall Street Journal.
  3. Ingham E (1 January 2021). "Mirati Therapeutics: Paying $220 A Share Sounds Excessive But Cracking KRAS Is A Big Deal (NASDAQ:MRTX)". Seeking Alpha.
  4. Garage JL (October 28, 2019). "Mirati drug shrinks tumors in some cancer patients in early-stage trial". CNBC.
  5. Tran H (31 December 2020). "Mirati Therapeutics: A Gift That Keeps On Giving (NASDAQ:MRTX)". Seeking Alpha.
  6. Speights K (26 October 2020). "Why Mirati Therapeutics Stock Is Taking Off Today". The Motley Fool.
  7. BNK Invest (29 March 2021). "RSI Alert: Mirati Therapeutics (MRTX) Now Oversold". NASDAQ.
  8. Whitlock J (7 July 2021). "Mirati Therapeutics Raises $234.3M in Public Stock Offering". San Diego Business Journal.
  9. Martz L (26 October 2019). "How a KRAS program transformed Mirati's story". BioCentury.
  10. Mirati (20 September 2021). "Mirati Therapeutics Appoints David Meek as Chief Executive Officer".
  • Official website
  • Business data for Mirati Therapeutics, Inc.:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.